Catheter Precision Received new VIVO Purchase Order from Leading Hospital in Slovenia
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) received a VIVO purchase order from University Clinical Center Ljubljana, a leading public hospital in Slovenia, expanding the company’s global commercial footprint to 15 countries. The company said the order and recent entries validate VIVO and LockeT adoption by physicians and follow a year of growth driven by distribution partnerships and ongoing navigation of international regulatory processes as it pursues further expansion in 2026.
Positive
- Received VIVO purchase order from University Clinical Center Ljubljana
- Global commercial footprint expanded to 15 countries
- Company cites physician validation of VIVO and LockeT products
- Established distribution partnerships and international market progress
Negative
- Purchase order value and shipment timing were not disclosed
- International regulatory navigation remains ongoing for expansion
News Market Reaction
On the day this news was published, VTAK declined 1.88%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While VTAK was down 5.75% pre‑announcement, peers showed mixed moves: NUWE down 20.17%, NAOV down 1.95%, but BBLG, BJDX and VERO up between 6.55% and 37.47%. Momentum scanner only flagged VERO moving down, indicating VTAK’s action appears stock-specific rather than a broad medical devices move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | LockeT expansion | Positive | +0.9% | Multi-year LockeT commitment in Ireland, expanding to an eighth European country. |
| Dec 03 | VIVO tender win | Positive | +13.3% | Multi-year VIVO tender in Hungary, first installation in the country. |
| Dec 01 | LockeT launch | Positive | -3.3% | Commercial launch of LockeT in Switzerland with strong initial feedback. |
| Nov 25 | Reimbursement change | Positive | +12.1% | CMS adds EP ablation codes to ASC list, framed as LockeT opportunity. |
| Nov 20 | LockeT uptake | Positive | -9.9% | Rapid LockeT uptake across five South African hospitals with reorders. |
Recent commercial and policy wins often produced positive but inconsistent price reactions, with both rallies and selloffs following seemingly favorable news.
Over the last few months, Catheter Precision reported a series of commercial and regulatory milestones. On Nov 20, 2025, a successful LockeT launch in South Africa saw rapid adoption but a -9.88% move. A reimbursement win for EP ablation in ASCs on Nov 25, 2025 coincided with a 12.13% gain. Subsequent European LockeT and VIVO expansion updates on Dec 1, Dec 3, and Dec 18, 2025 produced mixed reactions between -3.31% and 13.33%. Today’s Slovenia order extends this ongoing international footprint story.
Market Pulse Summary
This announcement extends Catheter Precision’s global footprint to 15 countries via a new VIVO order at a major Slovenian hospital, reinforcing ongoing European and international expansion. Recent history shows multiple commercial wins for both VIVO and LockeT alongside important reimbursement and regulatory updates. Investors may focus on how additional purchase orders, utilization levels at new centers, and forthcoming financial reports demonstrate whether this broader footprint translates into sustained revenue growth.
Key Terms
electrophysiology medical
ep lab medical
AI-generated analysis. Not financial advice.
Expands Global Footprint to 15 Countries
FORT MILL, S.C., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced receipt of a VIVO purchase order from University Clinical Center Ljubljana, a leading hospital in Slovenia. This expands Catheter Precision’s global sales footprint to 15 countries.
The University Clinical Center Ljubljana is a public health institution that provides healthcare services at secondary and tertiary levels, as well as educational and research activities. The University Clinical Center Ljubljana is the largest healthcare institution in Slovenia and among the largest hospitals in Central Europe.
“We are thrilled that we are growing our global sales footprint and now have products in 15 countries,” said David Jenkins, CEO of Catheter Precision. “Continued expansion validates that our products, both VIVO and LockeT, provide benefits to physicians by solving real-world challenges in EP Lab workflows and that physicians are finding our products are easy to use and effective for streamlining EP procedures and recovery after the procedures.”
This latest market entry follows a year of robust growth for Catheter Precision as the company continues to navigate international regulatory landscapes and establish strong distribution partnerships. With a presence now spanning 15 countries, the company is well-positioned to maintain its trajectory of global commercial expansion in 2026.
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What did Catheter Precision (VTAK) announce on January 20, 2026?
Which hospital placed the VIVO purchase order with Catheter Precision (VTAK)?
How does the January 20, 2026 purchase order affect Catheter Precision's global presence?
Does the Catheter Precision press release disclose the VIVO order value or delivery timing?
What products did Catheter Precision say physicians find beneficial in the announcement?
